Homocysteine lowering with folic acid and B vitamins in vascular disease

New England Journal of Medicine

Volumn 354, Issue 15, 2006, Pages 1567-1577

  Lonn, Eva ^a,b,i   Yusuf, Salim ^a,b   Arnold, Malcolm J ^c   Sheridan, Patrick ^a   Pogue, Janice ^a   Micks, Mary ^a   McQueen, Matthew J ^d   Probstfield, Jeffrey ^e   Fodor, George ^f   Held, Claes ^g   Genest Jr , Jacques ^h  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h ROYAL VICTORIA HOSPITAL   (Canada)

ⁱ HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; BLOOD; CEREBROVASCULAR ACCIDENT; DRUG COMBINATION; FOLLOW UP; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

AGED; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; VASCULAR DISEASES; VITAMIN B 12; VITAMIN B 6;

EID: 33645753544     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa060900     Document Type: Article

References (18)

1. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
2. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteineinduced endothelial injury and arteriosclerosis in baboons. Circ Res 1983;53:731-9.
3. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-43.
4. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
7. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31.
8. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
9. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
10. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-82.
11. 12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can J Cardiol 2006;22:47-53.
12. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69. [Erratum, J Am Coll Cardiol 2001;37:973.]
13. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
14. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
15. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.
16. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.
17. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-23. [Erratum, Lancet 2004;363:662.]
18. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.